



April 3, 2017
Announcement no. 06

Grant of Warrants to Employees and adjustment of EBIT forecast for 2017

According to the company's guidelines relating to incentive remuneration and the existing authorization in Section 18 of the Articles of Association, the Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has decided to issue new warrants to BioPorto's management and certain employees. A total of 4,350,000 warrants are issued. Because of the program's accounting impact, the EBIT forecast for the year 2017 is adjusted as further described below.

After the issuance of these warrants, the number of issued and not canceled warrants amounts to 7,500,000.

The issuance of new warrants will support the company's long-term goals and establish a performance-based remuneration reflecting the company's and shareholders' interests.

Each warrant grants the holder the right to subscribe for one share in the company. The exercise price is fixed at DKK 2.41 per share. Warrants will be exercisable from January 1, 2019 until December 31, 2022. Within the exercise period, warrants can be exercised within ordinary trading windows.

Conditions for cancellation of all warrants apply in case the Company does not achieve FDA approval of The NGAL Test™ before December 31, 2018. The program also includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of e.g. takeover bid, resolution and business transfer.

Detailed terms of the warrants are to be found in the Articles of Association on www.bioporto.com under Investor Relations> Governance> Company Articles.

The total number of shares that participants will be able to subscribe upon exercise of the warrants, are 4,350,000. The theoretical market value of the allocations of warrants amounts to DKK 2,681,340, of which DKK 1,037,562 relates to the financial year 2017. The statement is based on the Black-Scholes formula using an interest rate of -0.577% and the historical volatility of BioPorto A/S' shares of 24 months calculated to 71.5%. An assumption regarding the expected likelihood of vesting is set at two-thirds for the part of the program that is associated with conditions for cancellation.

Adjustment of earnings expectations

As a result of the program's accounting impact, the EBIT forecast for the year 2017 is adjusted: From a negative EBIT of around DKK 25-28 million, as announced in the annual report for 2016, to a negative EBIT of around DKK 26-29 million. The warrant program has no impact on cash flow.



For further information, please contact:

Thomas Magnussen, Chairman of the Board

Gry Husby Larsen, General Counsel

Telephone +45 4529 0000, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.